摘要
家族性高胆固醇血症(FH)是以血浆低密度脂蛋白胆固醇(LDL-C)异常升高、外周组织黄色瘤、动脉粥样硬化(AS)甚至早发冠心病为特征的常染色体显性遗传病。
出处
《中华内科杂志》
CAS
CSCD
北大核心
2013年第11期989-991,共3页
Chinese Journal of Internal Medicine
基金
国家自然科学基金(30971266)
二级参考文献22
-
1LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease[J]. N Engl J Med, 2005,352: 1425-1435.
-
2Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].N Engl J Med, 2004,350: 1495-1504.
-
3Gylling H, Miettinen TA. Baseline intestinal absorption and synthesis of cholesterol regulate its response to hypolipidaemic treatments in coronary patients [ J ]. Atherosclerosis, 2002,160 : 477 -481.
-
4Armitage J. The safety of statins in clinical practice [J]. Lancet, 2007,370 : 1781-1790.
-
5Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of Ezetimibe coadministered with Atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial[J]. Circulation, 2003,107:2409-2415.
-
6Howard G, Sharrett AR, Heiss G, et al. Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound [J]. Stroke, 1993,24: 1297- 1304.
-
7Herper M. More questions about Vytorin panel. Forbes, March 25, 2008. Available at www.forbes.com.
-
8Trip MD, van Wissen S, Smilde TJ, et al. Effect of Atorvastatin (80 mg) and Simvastatin (40 mg) on plasma fibrinogen levels and on carotid intima media thickness in patients with familial hypercholesterolemia [J]. Am J Cardiol, 2003,91 : 604-606.
-
9CASHMERE: Pfizer PhRMA Web Synopsis Protocol, A2581051, 29 October 2007 Final Report.
-
10Drazen JM, Jarcho JA, Morrissey S, et al. Cholesterol lowering and Ezetimibe [J]. N Engl J Med, 2008,358:1507- 1508.
同被引文献74
-
1Rizzo M,Battista Rini G. Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia[J]. Arch Med Sci ,2011,7( 1 ) :5-7.
-
2Izadi N, Malek M, Aminian O. Medical risk factors of diabetes mellitus among professional drivers [ J ], Journal of Diabetes and Metabolic Disorders,2013,12( 1 ) :23.
-
3Qazi MU, Malik S. Diabetes and Cardiovascular Disease:Orig- inal Insights from the Framingham Heart Study [J]. Global Heart,2013,8( 1 ) :43-48.
-
4Carvalho PM, Silva NJ, Dias PG. Glycogen Storage Disease type i a-a secondary cause for hyperlipidemia: report of five ca- ses [J]. Journal of Diabetes and Metabolic Disorders,2013,12 (1) :25.
-
5Polymeris A, Karoutsou E, Michalakis K. The impact of bariat- ric surgery procedures on type 2 diabetes, hyperlipidemia and hypertension [J]. Hellenic J Cardio, 2013,54 ( 3 ) : 212 -217.
-
6Willard-Grace R,Devore D ,Chert EH. The effectiveness of medi- cal assistant health coaching for low-income patients with uncon- trolled diabetes, hypertension, andhyperlipidemia: protocol for a randomized controlled trial and baseline characteristics of the study population [ J]. BMC Family Practice,2013,14( 1 ) :27.
-
7Lin CF, Gau CS, Wu FL, et al. Impact of ezetimibe coadmin- istered with statins on cardiovascular events following acute coronary syndrome: a 3-year population-based retrospective co- hort study in Taiwan[ J]. Clin Ther,2011,33(9) :1120-1131.
-
8Hiramitsu S, Ishiguro Y, Matsuyama H, et al. The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia [J]. J Athero- scler Thromb,2010,17 ( 1 ) : 106-114.
-
9Goldberg AC,Hopkins PN,Toth PP, et al.Familial hypercholesterolemia:screening, diagnosis and management of pediatric and adult patients:clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia[J].Clin Lipidol,2011,5(3suppl):S 1-8.
-
10Sjouke B,Kusters DM,Kastelein JJ,et al.Familial hypercholesterolemia:present and future management[J]. Curr Cardiol Rep,2011,13:527-536.
引证文献7
-
1周雪玲.依折麦布对糖尿病高胆固醇血症患者血脂、血糖和炎症指标的影响[J].实用药物与临床,2014,17(5):565-568. 被引量:8
-
2肖宏凯,蔡琴红,陈筱潮.女性急性冠脉综合征1例[J].中西医结合心血管病电子杂志,2015,3(10):197-198.
-
3吴蓝津.冠心病治疗方法的研究进展[J].按摩与康复医学,2016,0(11):8-9. 被引量:8
-
4陈祯玥,陆国平.家族性高胆固醇血症研究现状[J].国际心血管病杂志,2017,44(1):1-6. 被引量:3
-
5刘东慧.营心通脉方治疗冠心病心绞痛疗效分析[J].系统医学,2017,2(8):121-123. 被引量:1
-
6郭凤静,张大庆.家族性高胆固醇血症诊治进展[J].实用药物与临床,2018,21(9):1066-1072. 被引量:1
-
7任慧,鄂璐莎.与PCSK9相关的研究进展[J].内蒙古医学杂志,2021,53(7):824-826.
二级引证文献21
-
1吕洋,陈岩,齐文诚,Thanyaluk Charoenkham.他汀类药物联合依折麦布调脂治疗研究进展[J].辽宁中医药大学学报,2015,17(9):208-212. 被引量:6
-
2钟冬梅,陈镇涛,连运兴.依折麦布联合瑞舒伐他汀在2型糖尿病合并高脂血症患者中的临床研究[J].中国医药科学,2015,5(22):43-45. 被引量:12
-
3何莎.匹伐他汀对血糖的效应及其治疗糖尿病高胆固醇血症的效果观察[J].糖尿病新世界,2016,19(5):42-44. 被引量:3
-
4李剑,闫双通,龚燕平,卢艳慧,孙般若,成晓玲,李春霖,邵迎红.依折麦布联合瑞舒伐他汀治疗2型糖尿病合并高脂血症的临床效果[J].中国医药,2016,11(6):821-824. 被引量:22
-
5王爽,郑秀艳,孙文华,陈俊华,毛奎艳.阿托伐他汀联合依折麦布对冠心病患者氧化应激及血脂水平的影响[J].现代生物医学进展,2017,17(13):2470-2473. 被引量:29
-
6黄强,李明琰.替格瑞洛在冠脉介入治疗后的治疗效果及安全性临床观察[J].中国医药科学,2017,7(12):39-41. 被引量:6
-
7冯健,李坚,尤华彦.辛伐他汀联合左卡尼汀对冠心病合并糖尿病患者心功能的影响[J].糖尿病新世界,2017,20(11):107-108. 被引量:5
-
8杨勇.冠心病介入治疗的现状与研究进展综述[J].中西医结合心血管病电子杂志,2016,4(22):11-12. 被引量:7
-
9薛强,苑媛,孙静,裴海峰,薛松妍.中西医结合治疗对T2DM合并CHD患者血糖、血脂及血管内皮功能的影响[J].现代生物医学进展,2017,17(32):6299-6303. 被引量:10
-
10胡波,张晓刚,李德才.miR-22靶向抑制NLRP3基因对冠心病内皮细胞炎症损伤的保护作用[J].安徽医科大学学报,2018,53(5):668-675. 被引量:13
-
1李佳丹,赵振博,陈光辉.家族性高胆固醇血症合并动脉粥样硬化1例并文献复习[J].解放军医学院学报,2013,34(4):408-410. 被引量:3
-
2王蓓,林玲.家族性高胆固醇血症的临床与基因治疗新进展[J].中国动脉硬化杂志,2014,22(12):1287-1291. 被引量:8
-
3忻蓉,陆国平.家族性高胆固醇血症基因治疗现状[J].医学信息(中旬刊),2011,24(2):799-801.
-
4颜丽,朱江,何津祥,王广,何津春.家族性高胆固醇血症的临床诊断标准[J].兰州大学学报(医学版),2015,41(4):20-26. 被引量:6
-
5黄登鹏,王少军,吴平生,郭志刚.家族性高胆固醇血症24例分析[J].医学理论与实践,2003,16(10):1149-1150.
-
6闫菲菲,任杨源,张可人,赵馨,靳文,李志樑,傅强.家族性高胆固醇血症伴冠心病的病例报道及回顾分析[J].临床心血管病杂志,2013,29(7):542-544. 被引量:3
-
7蔡海江.我国家族性高胆固醇血症临床特点,诊断及治疗的研究进展[J].美国医学会杂志(中文版),1994,13(5):265-266. 被引量:7
-
8王家锦,穆莹,张骏,赵亚妹.家族性高胆固醇血症一例报告[J].中国优生优育(1990-2002上半年),1999,10(3):131-132.
-
9杜怀明,马咸成.家族性高胆固醇血症一例[J].中华儿科杂志,1996,34(1):70-70. 被引量:1
-
10李宝山,吕桂芝,白广林,刘金,常一杰.家族性高胆固醇血症的临床观察[J].中华医学遗传学杂志,1992,9(5):314-315. 被引量:1